{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:16Z","timestamp":1791277816226,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s13181-012-0276-5","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T22:05:32Z","timestamp":1354658732000},"page":"192-195","source":"Crossref","is-referenced-by-count":33,"title":["Positive Outcome After Intentional Overdose of Dabigatran"],"prefix":"10.1007","volume":"9","author":[{"given":"Jason S.","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Phanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"276_CR1","unstructured":"US-FDA. (2010) FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm230241.htm . Accessed 17 July 2012"},{"key":"276_CR2","unstructured":"US-FDA. (2011) FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm282724.htm . Accessed 5 May 2012"},{"issue":"5","key":"276_CR3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3171\/2012.2.JNS112132","volume":"116","author":"ST Garber","year":"2012","unstructured":"Garber ST, Sivakumar W, Schmidt RH (2012) Neurosurgical complications of direct thrombin inhibitors\u2014catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 116(5):1093\u20131096","journal-title":"J Neurosurg"},{"issue":"2","key":"276_CR4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.amjopharm.2012.02.004","volume":"10","author":"EL Cano","year":"2012","unstructured":"Cano EL, Miyares MA (2012) Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 10(2):160\u2013163","journal-title":"Am J Geriatr Pharmacother"},{"issue":"5","key":"276_CR5","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1002\/j.1875-9114.2012.01036.x","volume":"32","author":"CA Barton","year":"2012","unstructured":"Barton CA et al (2012) Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy 32(5):e103\u2013e107","journal-title":"Pharmacotherapy"},{"issue":"6","key":"276_CR6","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1345\/aph.1Q705","volume":"46","author":"J Bene","year":"2012","unstructured":"Bene J et al (2012) Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in two elderly patients. Ann Pharmacother 46(6):e14","journal-title":"Ann Pharmacother"},{"key":"276_CR7","doi-asserted-by":"crossref","unstructured":"Fellows SE et al (2012) Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. doi: 10.1016\/j.jemermed.2012.02.042","DOI":"10.1016\/j.jemermed.2012.02.042"},{"issue":"4","key":"276_CR8","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1345\/aph.1Q747","volume":"46","author":"MK Wychowski","year":"2012","unstructured":"Wychowski MK, Kouides PA (2012) Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 46(4):e10","journal-title":"Ann Pharmacother"},{"issue":"9","key":"276_CR9","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","volume":"119","author":"TE Warkentin","year":"2012","unstructured":"Warkentin TE et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9):2172\u20132174","journal-title":"Blood"},{"issue":"4","key":"276_CR10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2011.10.017","volume":"125","author":"J Ryn van","year":"2012","unstructured":"van Ryn J, Baruch L, Clemens A (2012) Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 125(4):417\u2013420","journal-title":"Am J Med"},{"issue":"17","key":"276_CR11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","volume":"69","author":"MA Miyares","year":"2012","unstructured":"Miyares MA, Davis K (2012) Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 69(17):1473\u20131484","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"276_CR12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1309\/AJCPAU7OQM0SRPZQ","volume":"137","author":"ST Avecilla","year":"2012","unstructured":"Avecilla ST et al (2012) Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 137(4):572\u2013574","journal-title":"Am J Clin Pathol"},{"key":"276_CR13","unstructured":"US-FDA. (2012) FDA advisory committee briefing document\u2014dabigatran etexilate (DE). http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf . Accessed 20 May 2012"},{"issue":"Suppl 1","key":"276_CR14","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1002\/ajh.23165","volume":"87","author":"KA Bauer","year":"2012","unstructured":"Bauer KA (2012) Reversal of antithrombotic agents. Am J Hematol 87(Suppl 1):S119\u2013S26","journal-title":"Am J Hematol"},{"issue":"5","key":"276_CR15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","volume":"107","author":"J Douxfils","year":"2012","unstructured":"Douxfils J et al (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107(5):985\u2013997","journal-title":"Thromb Haemost"},{"key":"276_CR16","doi-asserted-by":"crossref","unstructured":"Van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A. (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. In: 51st ASH Annual Meeting and Exposition, Ernest N. Morial Convention Center, New Orleans, 5-8 Dec 2009. https:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper21383.html . Accessed 15 May 2012","DOI":"10.1182\/blood.V114.22.1065.1065"},{"issue":"7","key":"276_CR17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1081\/CLT-200045006","volume":"42","author":"JA Vale","year":"2004","unstructured":"Vale JA, Kulig K (2004) Position paper: gastric lavage. J Toxicol Clin Toxicol 42(7):933\u2013943","journal-title":"J Toxicol Clin Toxicol"},{"issue":"Suppl 1","key":"276_CR18","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","volume":"87","author":"S Kaatz","year":"2012","unstructured":"Kaatz S et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141\u2013S145","journal-title":"Am J Hematol"},{"issue":"12","key":"276_CR19","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","volume":"42","author":"W Zhou","year":"2011","unstructured":"Zhou W et al (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594\u20133599","journal-title":"Stroke"},{"issue":"4","key":"276_CR20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J et al (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259\u2013268","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-012-0276-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0276-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:19:57Z","timestamp":1595027997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-012-0276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1007\/s13181-012-0276-5","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}